SABCS 2023 | Highlights from SABCS 2023: novel agents and insights on HER2 dynamics in breast cancer

Kevin M. Kalinsky, MD, MS, from the Winship Cancer Institute in Atlanta, GA, discusses exciting posters presented during the spotlight session at the San Antonio Breast Cancer Symposium (SABCS) 2023. The main focus is on new agents, including two bispecific antibodies and a TROP-2 antibody-drug conjugate (ADC). A real-world analysis, RELIEVE, underscores the importance of HER2 dynamics, revealing potential differences in outcomes for patients with HER2-low primary tumors and metastatic tumors. The discussion emphasizes considerations about toxicities, responses, and the optimal measurement of targets, questioning whether targeted therapies induce bystander effects that render assays less critical. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing, protected by global copyright laws. All rights are reserved.